CalciMedica, Inc. (CALC)
NASDAQ: CALC · Real-Time Price · USD
0.816
+0.190 (30.29%)
At close: Jun 26, 2026, 4:00 PM EDT
0.760
-0.056 (-6.85%)
After-hours: Jun 26, 2026, 7:56 PM EDT
Company Description
CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage.
Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.
The company also develops Auxora for the treatment of ulcerative colitis, traumatic brain injury, and allergic asthma; and oral CRAC channel inhibitors for use in chronic inflammatory and immunologic disease.
The company is based in La Jolla, California.
CalciMedica, Inc.
| Country | United States |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16 |
| CEO | A. Leheny |
Contact Details
Address: 505 Coast Boulevard South, Suite 307 La Jolla, California 92037 United States | |
| Phone | 858 952 5500 |
| Website | calcimedica.com |
Stock Details
| Ticker Symbol | CALC |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001534133 |
| CUSIP Number | 38942Q202 |
| ISIN Number | US38942Q2021 |
| Employer ID | 45-2120079 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. A. Rachel Leheny Ph.D. | Chief Executive Officer and Director |
| Eric W. Roberts | Chief Business Officer and Vice Chairman of the Board |
| Dr. Sudarshan Hebbar M.D. | Chief Medical Officer |
| Michael J. Dunn B.A., M.B.A. | President and Chief Operating Officer |
| Dr. Anjana Rao Ph.D. | Co-Founder and Scientific Advisor |
| Dr. Patrick Hogan Ph.D. | Co-Founder and Scientific Advisor |
| Dr. Stefan Feske M.D. | Co-Founder and Scientific Advisor |
| Dr. Kenneth A. Stauderman Ph.D. | Co-Founder and Chief Scientific Officer |
| Stephen B. Bardin | Chief Financial Officer |
| John M. Dunn J.D. | General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 25, 2026 | SCHEDULE 13G/A | Filing |
| Jun 24, 2026 | 8-K | Current Report |
| Jun 24, 2026 | 8-K | Current Report |
| May 20, 2026 | SCHEDULE 13G/A | Filing |
| May 12, 2026 | 10-Q | Quarterly Report |
| May 12, 2026 | 8-K | Current Report |
| May 8, 2026 | SCHEDULE 13G/A | Filing |
| Apr 30, 2026 | 10-K/A | [Amend] Annual report |
| Mar 18, 2026 | 8-K | Current Report |
| Mar 11, 2026 | EFFECT | Notice of Effectiveness |